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Abstract
Background: Animal-derived constituents are frequently used in anaesthesia and surgery, and patients are seldom
informed of this. This is problematic for a growing minority of patients who may have religious or secular concerns
about their use in their care. It is not currently common practice to inform patients about the use of animal-derived
constituents, yet what little empirical data does exist indicates that many patients want the opportunity to give
their informed consent.
Discussion: First we review the nature and scale of the problem by looking at the groups who may have concerns
about the use of animal-derived constituents in their care. We then summarise some of the products used in
anaesthesia and surgery that can contain such constituents, such as anaesthetic drugs, surgical implants and
dressings. Finally, we explore the problem of animal-derived constituents and consent using Beauchamp and
Childress’ four principles approach, examining issues of autonomy, beneficence, nonmaleficence and justice.
Summary: Disclosing the use of animal-derived constituents in anaesthesia and surgery is warranted under
Beauchamp and Childress’ four principles approach to the problem. Although there exist systemic and practical
challenges to implementing this in practice, the ethical case for doing so is strong. The Montgomery ruling
presents additional legal reason for disclosure because it entails that patients must be made aware of risks
associated with their treatment that they attach significance to.
Keywords: Animal-derived products, Informed consent, Vegetarianism, Veganism, Principlism, Montgomery,
Paternalism, Anaesthesia, Surgery, Dressings
Background
Providing healthcare in a culturally diverse society can
involve a number of unique challenges and compromises.
The problem of animal-derived products in healthcare has
received some attention in the literature [1–3]. However,
very few clinicians remain aware of the scale of the
problem, and even fewer have considered how it could be
navigated in a way that respects the rights and interests of
patients. When so many individuals and groups differ on
fundamental concepts, what constitutes care for one
patient could be interpreted as harm by another. Some of
these fundamental disagreements surround the ethical
permissibility of products utilised in healthcare that
contain an animal-derived constituent.
Patients with certain religious and secular beliefs may
express concerns about the use of animal-derived con-
stituents in their care, and in some cases, this can result
in a patient refusing certain kinds of treatment [1, 4–6].
The area of perioperative care is notably problematic be-
cause of the broad range of products employed that may
contain animal-derived constituents, such as anaesthetic
drugs, surgical implants and dressings. An increasing
number of individuals would like to and may even ex-
pect to be informed of any animal-derived constituents
that could be used in their care.
The United Kingdom (UK) represents a diverse and
multicultural population who hold a variety of religious
and secular beliefs about the permissibility of using
animals for food, clothing, research or medical products,
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and this population is increasing. Between the 2001 and
2011 censuses, the Muslim population in England and
Wales increased by 1.2 million, and from 3% to 5% of
the total population [7]. For Muslims, products contain-
ing animal-derived constituents are unlikely to be
halal—compatible with Islamic dietary laws. Further-
more, research commissioned by The Vegan Society
found that about 1% or over 500,000 of the over-15 UK
population now follow a vegan diet which amounts to
more than a 300% increase since 2006—a significant
proportion of who avoid non-dietary animal products
[8]. This steep increase in both the Muslim and vegan
populations implies that the number of individuals who
might object to the use of animal-derived products used
in healthcare is growing rapidly. This raises some signifi-
cant ethical and practical issues for clinicians, the most
pertinent being deciding what information should or
should not be disclosed to patients about the products
being used to treat them.
The importance of disclosure has been recently
highlighted by the Montgomery v Lanarkshire Health
Board [2015] case, which has transformed UK law on
informed consent [9]. With regard to informing the pa-
tient of any material risks involved in their treatment,
the Montgomery ruling shifts the emphasis from what
clinicians would agree is reasonable, to what a reason-
able patient would expect to know. The ruling means
that clinicians must communicate relevant information
to a patient, even if its disclosure could lead the patient
to make a choice that may not be in their best interest
[10]. Patients are entitled to make decisions that a clin-
ician disagrees with, unless they lack capacity to make
an informed choice [11]—even if a clinician is concerned
that disclosing certain information could cause psycho-
logical harm or lead a patient to refuse life-saving
treatment [12].
In this article, we explore which patients may wish to
be informed about the use of animal-derived constitu-
ents in their anaesthetic and surgical care, and then de-
scribe some of the products that may contain them. We
then consider some of the ethical issues associated with
using these products in anaesthesia and surgery.
Employing Beauchamp and Childress’ influential four
principles of bioethics—autonomy, beneficence, nonma-
leficence and justice—we examine the case for disclosing
this information to patients and the potential challenges
of doing so [13].
Who has concerns about the use of animal-derived
constituents?
In 2017, the Vegan Society sent a letter to the UK’s
Secretary of State for Health, detailing their concerns
about the use of animal-derived constituents in health-
care, and the current lack of transparency on the
labelling of medicines [14]. Understandably, the growing
number of vegetarians and vegans want to know if the
drugs they might be prescribed contain animal-derived
constituents. Individuals are increasingly restricting their
consumption and use of animal-derived products for a
number of reasons: perceived health benefits, environ-
mental concerns, ethical reasons such as promoting
animal welfare, and objections to the intentional killing of
non-human animals [15]. It has been estimated that be-
tween 3 and 7% of the UK population are vegetarian [16].
Importantly, not all vegetarians would necessarily
object to the use of drugs, dressings or implants that
have animal-derived constituents. Merely being vegetar-
ian does not necessarily entail objecting to the use of
animal-derived products, since some reasons for being
vegetarian may not extend beyond dietary preferences
[2]. This is in contrast with vegans who typically will not
eat or use dairy products, eggs or other animal-derived
products. Vegans are much more likely to have concerns
about any animal-derived products that may be used in
their care, and will want to be fully informed. Many will
wish to avoid animal-derived products as far as possible
and opt for an alternative, should one exist. Charlotte
Houltram, a vegan anaesthetist, has stated that achieving
an animal-derived product free anaesthetic can be prac-
ticable and offers helpful guidance on how to do so [17].
Houltram notes that because all drugs currently in use
in the UK have been tested on animals during their
development, none of them can be considered to be fully
vegan. Consequently, their use will always involve a
degree of compromise.
There is also a more sizeable population who poten-
tially may object to the use of animal-derived products
in anaesthesia and surgery for religious reasons. In one
survey of 13 representative religious leaders, 10 (77%)
expressed concerns about the use of biological prod-
ucts—including those with animal-derived constitu-
ents—in healthcare and thought that informed consent
should be obtained from patients [18]. A subsequent
study by Eriksson et al. explored which religious groups
object to the use of drugs, implants and dressings con-
taining animal-derived constituents [19]. It was discov-
ered that a number of the world’s largest religions
objected to the use of some animal-derived products.
For example, Muslims—Sunni and Shiite—in the study
objected to the use of any porcine-containing products.
In Islam, pork and its by-products are considered
‘haram’ which means forbidden and so for some
Muslims the use of porcine-containing products is im-
permissible, even if the alternative non-porcine contain-
ing product—should one exist—meant that healing and
recovery was delayed or it was more expensive [18, 20].
For some Muslims, what would be unlawful to consume
can also be considered unlawful in the context of
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healthcare [21]. Nevertheless, Islam is not homogenous
and there remains no definitive consensus regarding the
use of products that contain an animal-derived constitu-
ent [20, 22]. Individual Muslims may therefore have
differing beliefs and ways to navigate such conflicts
should be considered [21].
Hindus from one of the major traditions known as
Vaishnavism objected to the use of drugs, implants and
dressings that contain porcine and bovine constituents
[19]. This view may not necessarily be representative of
all of the traditions within Hinduism, although the ma-
jority are vegetarians and avoid egg. However, the use of
any animal-derived products may be problematic for
many Hindus, with many categorically rejecting their
use [1, 23]. The Christian, Jewish and Buddhist leaders
contacted by Eriksson et al. had no objections to any
animal-derived products [19]. However, all of the
religious groups that objected to the routine use of
animal-derived products stated that they would be per-
missible providing (1) there was no viable alternative
and (2) they were required for emergency treatment
[19]. However, what is classed as emergency treatment
can be ambiguous. Some kinds of surgical procedure
containing animal-derived products may not be
life-saving, but they may have a substantial positive im-
pact on a patient’s long-term quality of life and general
wellbeing.
Neither religious or secular groups are homogeneous
in their views on the use of animal-derived products
used in their care. Consequently, there is considerable
diversity of opinion, and membership of a particular
group does not necessarily dictate an individual’s convic-
tions. The increase in the number of religious and secu-
lar individuals who might be concerned about the use of
animal-derived constituents indicates that this is an issue
healthcare professionals can no longer afford to ignore.
Drugs, dressings and implants containing animal-derived
constituents
A number of products used in anaesthesia and surgery
contain animal-derived constituents that some patients
may object to, were they to know. What is particularly
problematic is that patients who may have concerns are
rarely informed that some of the products utilised in
their care may contain animal-derived constituents.
These include a number of anaesthetic drugs, surgical
implants and dressings. For instance, some drugs con-
tain animal-derived excipients (substances that do not
contribute to the therapeutic action), which can make
up 90% of the formulation [24]. These cannot always be
easily identified because there is currently no legal
requirement for them to be included on the packaging.
In one study it was discovered that of the 100 most
prescribed drugs in primary care in the UK, 74
contained an animal-derived ingredient (most commonly
bovine and porcine sources) [3]. This highlights the scale
of the problem for religious and secular patients who
may object to the use of products with animal-derived
constituents. For instance, amoxicillin capsules can be
prescribed postoperatively before discharge, yet they
contain porcine or bovine sourced gelatin, which is
widely used to encapsulate medication [25]. Some cap-
sules can be opened to avoid ingesting the gelatin, but
this is not always advisable, unless clearly stated on the
patient information leaflet. However, amoxicillin in oral
suspension is suitable for vegans and is one alternative
for patients who would prefer to minimise their use of
animal-derived constituents.
The most commonly used induction agent in anaes-
thesia—Propofol—contains purified egg phosphatide,
which vegans would want to avoid, and as it is likely the
eggs used are not free range, many vegetarians would
similarly find its use problematic [17, 26]. Avoiding Pro-
pofol is not an insurmountable problem and could be
managed relatively easily by an anaesthetist but it will
depend on the kind of induction that is clinically indi-
cated. There is a formulation of Propofol called Cleofol®,
which is manufactured in India and does not contain
any egg phosphatide or other animal-derived constitu-
ents [27]. However, its use has been associated with ex-
cessive pain on injection [28]. This may not be sufficient
to rule out the use of Cleofol® as a viable alternative for
patients who wish to avoid animal-derived constituents.
After all, a well known side-effect of Propofol is pain on
injection, which occurs in 60% of untreated patients;
pain on injection can be mitigated by using an antecubi-
tal vein or pre-treatment with intravenous (IV) Lido-
caine [29]. Moreover, Houltram suggests that patients
could avoid Propofol by opting for local or regional an-
aesthesia, or where appropriate by using an induction
agent that does not contain any animal-derived constitu-
ents such as Thiopentone, or by having a gas rather than
IV induction [17]. She does note that having a gas
induction may be contraindicated in some cases.
Hydrocolloid dressings can contain porcine-derived
gelatin and are routinely used for a number of different
types of hip and knee surgery [30, 31]. Most commonly
in the form of DuoDERM® which can also be used to
help secure endotracheal tubes (ETT) or nasopharyngeal
airways, and protect skin integrity in neonates and in-
fants [32, 33]. In a study by Enoch et al. published in
2005, it was discovered that very few healthcare profes-
sionals were aware of which commonly used dressings
contained biological material, and were therefore not
necessarily in a position to inform patients [18]. Enoch
et al. subsequently recommended that hospitals, higher
education institutions and product manufacturers should
take immediate action to ensure that healthcare
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professionals are educated about the biological products
they frequently use [18]. The lack of education and easily
available information creates a barrier to informing pa-
tients who might object to the use of certain biological
products, including those with animal-derived constitu-
ents. However, there is little evidence to suggest that
much has changed in more than a decade.
There are also a number of surgical products or implants
that could also be objectionable to a number of patients.
These include composite and biological mesh commonly
used to repair the abdominal wall during hernia surgery
and in some types of colorectal surgery [4, 34]. They fre-
quently use ingredients from porcine or bovine sources,
and this information is not always easily accessible. Bio-
polymer sutures can also contain animal-derived constitu-
ents, including those from ovine and bovine sources [35].
Other types of surgical products that can contain
animal-derived constituents include orthopaedic spacers,
heart valves and haemostasis matrix [19].
This brief summary of animal-derived products used
in anaesthesia and surgery shows that clinicians are rou-
tinely using drugs, dressings and surgical implants that a
sizable minority of patients in the UK may have a mater-
ial interest in being informed of. We are not suggesting
that there are any easy answers: we are keenly aware of
the existing systemic obstructions, and some of the rea-
sons clinicians may be hesitant to acknowledge that this
practice could be ethically problematic enough to war-
rant any serious concern. The health service is already
over-stretched, under-resourced, understaffed and many
clinicians are already struggling to provide patient care
under those existing constraints. Nevertheless, the
General Medical Council’s guidance on personal beliefs
and medical practice state that when ‘…assessing what is
of overall benefit to adult patients, you must take into
account their cultural, religious or other beliefs and
values’ [36]. In principle, it does not seem unreasonable
to us to conclude that this guidance implies that patients
should be informed about the use of animal-derived
products in their care. Furthermore, surgical (and
medical) inpatients are routinely asked about their diet-
ary requirements; there is no expectation that they must
self-declare that they require vegan, halal or kosher food.
It seems inconsistent to go to the effort and expense of re-
specting patient’s religious or secular dietary choices and
then use products in their care that many of them may
feel as strongly about. Informing patients can therefore
demonstrate a more holistic approach to their religious or
secular beliefs, rather than maintaining what could be
interpreted as a paternalistic approach to the issue.
Applying the four principles approach
We indicated that Beauchamp and Childress’ four prin-
ciples approach will be used to examine the issue of
disclosure of animal-derived products in anaesthesia and
surgery. We will consider what each principle informs
us about the problem, and attempt to weigh any com-
peting concerns that are uncovered. Beauchamp and
Childress recommend a process of deliberation to decide
the relative weights of each norm in this context, so that
balancing judgements can be made if conflicts between
principles are found when they are applied [13]. Beau-
champ and Childress offer some practical conditions for
restricting balancing to prevent the process from being
too open-ended, such as requiring that any infringement
of a principle is the least possible infringement with no
better alternative, and has realistic prospects of achiev-
ing the objective [13].
Autonomy
The first principle is respect for autonomy: acknowledg-
ing a patient’s right to make choices based on their per-
sonal values and beliefs, the paradigmatic example being
obtaining their informed consent before treatment. One
of the key elements of informed consent is disclosure of
relevant information, including ‘those facts or descrip-
tions that patients or subjects usually consider material
in deciding to refuse or consent to the proposed inter-
vention or research’ [13]. Typically, disclosure might in-
volve factors such as risks and benefits of a procedure,
but Beauchamp and Childress also suggest disclosure
should be ideally tailored to ‘the specific informational
needs of the individual person’, needs which might
include ‘unconventional beliefs’ [13]. Although only a
small minority of the population is vegan, there are also
significant numbers of people who avoid certain
animal-derived foods for religious reasons, and there is
widespread acceptance of disclosure of the use of
animal-derived products in the food industry. As already
noted, it is common practice in UK hospitals to request
inpatient preferences for their dietary requirements,
religious or otherwise.
It seems reasonable to inform patients of the use of
animal-derived products in their treatment, even if it is
not possible to avoid their use. Although the recent
Montgomery v Lanarkshire Health Board [2015] case
concerned clinical risks that could lead to patients being
harmed, it has established a precedent in the UK that
the patient’s autonomy must be respected—the patient
must be made aware of material risks involved in a rec-
ommended treatment as well as reasonable alternatives
[9]. A risk is defined as material if the patient is likely to
attach significance to this risk. Although in the context
of the Montgomery case this refers to risks of the med-
ical procedure, the legal implications could be broader:
arguably, some patients could be harmed by being
treated with animal-derived products if they have strong
moral or religious concerns and they later learn this has
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occurred. It is not for clinicians to assess the significance
of this risk on their patient’s behalf. Autonomy as under-
stood by Beauchamp and Childress entails that autono-
mous agents have the right to act according to their
values and beliefs [13]. If a clinician, for instance, knows
that their patient is Hindu, Muslim or vegan and fails to
disclose the use of known animal-derived products in
their care, they may be disrespecting their patient’s
autonomy.
Do patients want to know this information? Respect
for patient autonomy entails a presumption that they do,
and this has been reinforced by the Montgomery ruling.
One study from the United States (US) found that 84%
of patients sampled were unaware that over 1000
medications contain animal-derived constituents, and
63% wanted their physicians to inform them about
medications that contained these products [37]. This
provides empirical support for the claim that many
patients would prefer to be informed about the use of
animal-derived constituents in their care. Interestingly,
70% of physicians believed that providing their patients
with this information was important, although acknow-
ledging this seldom lead to any changes in practice [37].
The available evidence therefore indicates that a sig-
nificant proportion of patients may want this informa-
tion disclosed to them, and given the importance of
respect for patient autonomy, this implies clinicians
should not presume patients are uninterested but rather
ascertain if the use of animal-derived constituents is an
issue for them. If so, they should, as far as possible, dis-
close the use of known animal-derived constituents in
the patient’s care to ensure their concerns are adequately
catered for.
Nonmaleficence
The second principle is nonmaleficence, or the obliga-
tion not to inflict harm. According to Beauchamp and
Childress, harm is a thwarting, defeating, or setting back
of some party’s interests, and it is a prima facie principle
that harmful actions must be sufficiently justified [13].
While this commonly refers to physical harm, it also
encompasses psychological harms, which describes
harms that can damage someone’s psychological
well-being. As we indicated earlier, patients who may be
concerned about the use of animal-derived products in
their care may consider that they have been psychologic-
ally harmed by not having that information disclosed,
and later learning they have been treated with
animal-derived products without their consent.
Clinicians may consider such objections unconven-
tional and obstructive, nevertheless, harm can be very
subjective and individualistic, and a clinician cannot pre-
sume any resulting psychological harms would be trivial.
Some vegetarians have described feeling defiled at the
thought of accidentally eating meat—anecdotal accounts
describe such an experience as ‘upsetting’—and so it is
possible that failing to convey the use of an
animal-derived product could cause some degree of
psychological harm [38, 39]. Of course, there may not be
an alternative available, and it might be that a clinician
considers it is justified in avoiding disclosing such infor-
mation on the grounds that the patient may be harmed
if they refuse treatment.
Potential harm from the patient’s refusal to accept
treatment does not, however, seem sufficient grounds to
trump the combination of respect for patient autonomy
and the potential of later psychological harm. Failure to
disclose the information on the basis that the patient
may make a decision that may not be in their interest is
also not compatible with the Montgomery ruling. Unless
the patient lacks capacity to make an informed choice,
they are entitled to refuse treatment if they believe that
doing so would harm them, and even if doing so could
lead to additional harms. We have already established
that some patients would object to the use of
animal-derived products on religious or secular grounds,
and it seems likely they may be distressed to learn that
products with these constituents were used in their
treatment, without their consent. Previous studies have
identified that most religions make a provision for the
use of animal-derived product in an emergency—such as
life-prolonging surgery—or when all options for a clinic-
ally appropriate alternative have been exhausted [1, 19].
Nonmaleficence entails an obligation on clinicians to
not impose unnecessary harms; disclosing this informa-
tion and gaining informed consent would be one appro-
priate measure to avoid causing this kind of harm.
Beneficence
The principle of beneficence is closely related to nonma-
leficence—the requirement to contribute to the welfare
of the patient (rather than harm them) by acting in their
best interest. It is important to consider if disclosure of
the use of animal-derived products in perioperative care
will hinder patient welfare in some way. Obviously, the
patient’s treatment will be intended to benefit them, and
it is possible that disclosing this information could result
in the patient refusing certain kinds of treatment. This is
not just a theoretical concern, as we noted in our
introduction and discussed in the previous section.
Sattar et al. describe four cases of medication
non-adherence because of patients’ concerns about the
use of certain animal-derived constituents that they be-
lieved to be forbidden by their religion [40]. The patients
only stopped taking their medication upon finding out
for themselves that it contained an animal-derived
constituent. This led to either worsening symptoms or
relapses of their illness, and therefore a violation of the
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principle of beneficence. Naively, withholding informa-
tion might be thought to promote beneficence because
of the risk that some patients might decline treatment,
but as these examples show, some patients will investi-
gate for themselves. Consequently, in these four cases of
medication non-adherence, the cause was the absence of
disclosure and any conversation about the contents of
their medication prior to them being prescribed. All four
patients were subsequently provided with medication
that did not contain an animal-derived constituent and
that satisfied their religious concerns. Beneficence in
these cases would have been achieved by disclosing this
information, obtaining informed consent and amending
the medication in light of the patient’s religious beliefs.
A UK questionnaire-based study of a mixed ethnicity
inner-city population found that 43% would avoid taking
prescribed oral medication containing animal-derived in-
gredients, even if there was no alternative treatment
[41]. However, only 20% of those who preferred vegetar-
ian medication would ask the prescribing doctor if their
medication contained animal-derived ingredients. In the
perioperative context, this highlights the importance of
communicating the possibility of animal-derived constit-
uents being used to pre-empt these concerns. This rein-
forces our earlier point regarding the potential harm
that may eventuate from the use of these constituents
and the subsequent discovery of this by patients who
have strong religious or secular concerns with their use.
There is still the issue of those patients who refuse
treatment because of their convictions. What course of
action should be taken in these situations? It seems that
there is an obligation to ensure that alternative products
are available where possible, at least for commonly used
products. In addition, patient disclosure should include
variations in risks and benefits incurred by using alterna-
tive products, and of course if a suitable alternative ex-
ists and is available. Alternatives may not be available in
emergencies, but we have noted that religious groups
and vegans may not object to the use of animal-derived
constituents in these situations in the absence of alterna-
tives. Clinicians could also suggest, where possible, that
the patient discuss their concerns with a religious leader
or secular authority. In instances where a patient still re-
fuses treatment because of unavoidable animal-derived
constituents, the patient’s wishes must be respected, pro-
vided they have capacity to make an informed choice.
Justice
The final principle is justice, or the equitable distribution
of goods—healthcare in this case. We do not have space
to discuss different principles of distributive justice that
could be employed, or whether there is a general right
to healthcare and how it might be implemented. For our
purposes, we will assume that all patients deserve a
minimum standard of care, and the standard provided
should be equivalent for each patient. In practice,
healthcare resources are always finite, demands are high,
and consequently some form of rationing and setting of
priorities is always required. We can grant a prima facie
obligation to provide groups with certain religious or
moral convictions about animal-derived products with
alternative products so they can receive equivalent care,
but budgetary limitations may constrain what can be of-
fered. Constraints include the availability and affordabil-
ity of viable alternatives. Additionally, clinicians must be
aware of these alternatives, and be able to provide an as-
sessment of their comparative efficacy and risks. These
constraints are considerable, and we must ask, to what
extent should clinicians and budgets be required to cater
for patients with these convictions? The answer will be
dependent on each hospital’s budget, as well as the
particular product involved—some alternatives may be
considerably more expensive than the equivalent
animal-derived product.
An additional consideration, raised by Newson, is that
some synthetic alternatives may have greater efficacy
than their equivalent [42]. This may mean that those pa-
tients with religious and moral convictions about the use
of animal-derived constituents may receive more effect-
ive treatment than most patients, which seems unjust.
The solution may be to provide the synthetic version to
all patients, but if this incurs significantly increased
costs, it may impact the provision of health services in
other ways, and this may not be acceptable. Of course,
some non-animal-derived drugs may well be less effect-
ive than their equivalents, but in these scenarios, the
patient can be given the choice of either drug.
For synthetic alternatives that prove too expensive, there
is another approach that could be considered. The mini-
mum standard of care provided could exclude the
provision of synthetic drugs except where they incur simi-
lar costs, and patients whose convictions require them to
avoid animal-derived products could pay for these alterna-
tives themselves, either via a private health insurance
policy designed for the purpose, or directly. If such a pol-
icy is made widely known, over time those who hold such
convictions could ensure they make provision for this.
What are the implications for disclosure? If, as a matter
of policy, all clinicians were required to disclose the use of
animal-derived products to their patients, demand for al-
ternatives would increase and ultimately costs of these al-
ternatives should decrease. In many instances, synthetic
alternatives could gradually replace certain animal-derived
products for all patients. This would, over time, make
healthcare more accessible for those who hold convictions
about the use of animal-derived products. There are,
however, a number of complications that could ensue and
which we now briefly explore.
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Challenges of disclosure
We have sought here to make the ethical case for
disclosure by considering the problem using Beauchamp
and Childress’ four principles approach. We will now re-
view some of the challenges that implementing it might
generate in anaesthesia and surgery and beyond. It is
primarily problematic for a very practical reason: very
few clinicians know whether or not the drugs, surgical
products and dressings they use contain any
animal-derived constituents. Additionally, as Tatham
and Patel note, ‘information about animal derived prod-
ucts in medicines is difficult to obtain, unclear, inconsist-
ently reported, and sometimes incorrect’ [3]. Even
clearer labelling, however, is not sufficient, as a compre-
hensive knowledge is also required of what acceptable
alternatives—should they exist—to each drug or product
are available, including efficacy and comparative risks.
These types of systemic obstructions mean that
clinicians are limited in what they can actually promise a
patient if they request that they want their care to be
free of animal-derived constituents. Clinicians can
undertake to minimise their use, but will need to com-
municate that insufficient information exists regarding
the constituents in every product they are using, and so
it is possible that some products may still contain
animal-derived constituents. Any more than this may
not be practicable until there has been significant
changes in product labelling. In some cases, surgeons
will know that a product—such as a biological surgical
mesh containing porcine tissue—contains a constituent
that a patient may object to, and here we have estab-
lished that patient concerns should be preempted and
informed consent should be obtained. In the context of
anaesthesia, it may be possible for an anaesthetist to
provide an ‘animal product free anaesthetic’ for patients,
providing as we have already discussed, that this is
compatible with the kind of induction that is clinically
indicated [17]. This does still raise additional clinical
concerns: it is conceivable that in trying to meet the
demands of patients who want an ‘animal product free
anaesthetic’ that this could lead to an increased risk of
anaesthetic complications. For instance, the use of Thio-
pentone in obstetrics has been associated with increased
drug errors, and it is relatively unfamiliar to the newer
generation of anaesthetists who most frequently use
Propofol to induce patients [43].
The task of disclosure would be far easier if a legal
requirement was introduced forcing the declaration of
inactive animal-derived constituents. A database of
medicines licensed for use in the UK already exists: the
electronic Medicines Compendium (eMC) [44]. The
eMC contains a Summary of Product Characteristics
(SmPC) for each medicine, which is comprised of
detailed information supplied by pharmaceutical
companies, including active and inactive constituents.
This information is checked and approved by the UK or
European government agencies which licence medicines.
It would be straightforward to augment the existing data
to indicate what constituents are animal-derived, and
this would be a significant step forward, at least for med-
icines. However, dressings and surgical implants are not
included in this compendium. Additionally, knowledge
of acceptable alternatives—should they exist—to each
drug or product are required, including efficacy and
comparative risks. It seems feasible to include this infor-
mation, although this would be a more complex task.
This would be broadly useful in healthcare far beyond
anaesthesia and surgery, and indeed, the case for disclos-
ure presented here is likewise widely applicable.
A long-term solution, suggested by Tatham and Patel,
would be to eliminate all animal-derived constituents
from all drugs and medical products [3]. This may seem
unlikely in the short-term, given the number of products
that would require modification or replacement, and the
potential costs that would ensue. There are also no
incentives for medical and pharmaceutical companies to
even consider this development. However, were disclos-
ure to be advocated, clinicians and patients could exert
pressure on companies to develop products that would
alleviate their religious or secular concerns. Finally, an
important component of successful disclosure is
improved education among healthcare professionals
regarding the use of animal-derived constituents. Higher
education institutions must consider their responsibility
to educate healthcare professionals about the ethical and
legal issues surrounding the use of animal-derived
products in healthcare.
Conclusion
The use of animal derived constituents in anaesthesia
and surgery is of increasing interest for a growing
minority of patients, many of whom have religious or
secular concerns about their use. There has been a
significant rise in the Muslim and vegan populations in
the UK, and we have argued that existing research sup-
ports the contention that many of them believe that they
should be given the opportunity to provide informed
consent. Clinicians should expect to be increasingly con-
fronted by patients who wish to know if any products
used in their care contain animal-derived constituents,
and whether they can be avoided. Clinicians must there-
fore consider how they will manage the concerns of such
patients.
We have applied Beauchamp and Childress’ four
principles to this issue, and conclude that they provide a
strong case for disclosing the use of animal-derived
constituents to patients in anaesthesia and surgery, as
well as other areas of healthcare. The importance of
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patient autonomy provides the strongest argument for
disclosure. The Montgomery ruling, while a legal
motivation rather than an ethical one, also emphasises
the importance of patient expectations about disclosure,
and we have established that for many patients, the use
of animal-derived constituents is a significant issue.
We acknowledge that full disclosure faces some
practical difficulties at present: there are a number of
systemic obstructions that will need to be dealt with
which will require significant changes to the law, prod-
uct development, education and clinical practice. Never-
theless, our analysis strongly supports the contention
that informed consent should be gained from patients
when animal-derived constituents will be used in their
care, and that alternatives should be sought where
available and practicable.
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